

RECEIVED  
CENTRAL FAX CENTER

Docket No.: PRD-2014USPCT  
U.S.S.N. 10/507,084


JAN 16 2009

Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-27 (cancelled).

28. (previously presented) A compound of formula (I),



the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein

t is 0, 1, 2, 3 or 4 and when t is 0 then a direct bond is intended;

each Q is ;

each X is nitrogen;

each Y is nitrogen;

each Z is -NH-, or -O-;

R<sup>1</sup> is -C(O)NR<sup>3</sup>R<sup>4</sup>, -NHC(O)R<sup>7</sup>, -C(O)-C<sub>1-6</sub>alkanediylSR<sup>7</sup>, -NR<sup>6</sup>C(O)N(OH)R<sup>7</sup>, -NR<sup>6</sup>C(O)C<sub>1-6</sub>alkanediylSR<sup>7</sup>, or -NR<sup>6</sup>C(O)C=N(OH)R<sup>7</sup> wherein R<sup>3</sup> and R<sup>4</sup> are each independently selected from hydrogen, hydroxy, C<sub>1-6</sub>alkyl, hydroxyC<sub>1-6</sub>alkyl, aminoC<sub>1-6</sub>alkyl or aminoaryl;

R<sup>7</sup> is independently selected from hydrogen, C<sub>1-6</sub>alkyl, or C<sub>1-6</sub>alkylcarbonyl;

R<sup>6</sup> is independently selected from hydrogen or C<sub>1-6</sub>alkyl;



R<sup>2</sup> is hydrogen, hydroxy, amino, hydroxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, arylC<sub>1-6</sub>alkyl, aminocarbonyl, hydroxycarbonyl, aminoC<sub>1-6</sub>alkyl,

Docket No.: PRD-2014USPCT  
U.S.S.N. 10/507,084

aminocarbonylC<sub>1-6</sub>alkyl, hydroxycarbonylC<sub>1-6</sub>alkyl, hydroxyaminocarbonyl,  
C<sub>1-6</sub>alkyloxycarbonyl, C<sub>1-6</sub>alkylaminoC<sub>1-6</sub>alkyl or di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl;

-L- is a bivalent radical selected from -NR<sup>9</sup>C(O)-, -NR<sup>9</sup>SO<sub>2</sub>- or -NR<sup>9</sup>CH<sub>2</sub>-  
wherein R<sup>9</sup> is hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-10</sub>cycloalkyl, hydroxyC<sub>1-6</sub>alkyl,  
C<sub>1-6</sub>alkyloxyC<sub>1-6</sub>alkyl or di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl;

... (A) is a radical selected from



wherein each s is independently 0, 1, 2, 3, 4 or 5;

R<sup>5</sup> is selected from hydrogen or phenyl optionally substituted with one, two or three  
substituents independently selected from halo, amino, nitro, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy,  
hydroxyC<sub>1-4</sub>alkyl, trifluoromethyl, trifluoromethyloxy, hydroxyC<sub>1-4</sub>alkyloxy,  
C<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkyloxycarbonyl,  
aminoC<sub>1-4</sub>alkyloxy,  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyloxy, di(C<sub>1-4</sub>alkyl)amino, di(C<sub>1-4</sub>alkyl)aminocarbonyl, di(C<sub>1-4</sub>  
alkyl)aminoC<sub>1-4</sub>alkyl, di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl,  
di(C<sub>1-4</sub>alkyl)amino(C<sub>1-4</sub>alkyl)amino, di(C<sub>1-4</sub>alkyl)amino(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl(C<sub>1-4</sub>alkyl)amino,  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,

Docket No.: PRD-2014USPCT  
U.S.S.N. 10/507,084

aminosulfonylamino(C<sub>1-4</sub>alkyl)amino,  
aminosulfonylamino(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,  
di(C<sub>1-4</sub>alkyl)aminosulfonylamino(C<sub>1-4</sub>alkyl)amino,  
di(C<sub>1-4</sub>alkyl)aminosulfonylamino(C<sub>1-4</sub>alkyl)aminoC<sub>1-6</sub>alkyl, cyano,  
(hydroxyC<sub>1-4</sub>alkyl)(C<sub>1-4</sub>alkyl)amino, (hydroxyC<sub>1-4</sub>alkyl)(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,  
hydroxyC<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl, di(hydroxyC<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkylamino, di(hydroxyC<sub>1-4</sub>alkyl)amino, or  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkylamino;

R<sup>6</sup> is selected from hydrogen; halo; hydroxy; amino; nitro; trihaloC<sub>1-6</sub>alkyl; trihaloC<sub>1-6</sub>alkyloxy; C<sub>1-6</sub>alkyl; C<sub>1-6</sub>alkyl substituted with aryl and C<sub>3-10</sub>cycloalkyl; C<sub>1-6</sub>alkyloxy; C<sub>1-6</sub>alkyloxyC<sub>1-6</sub>alkyloxy; C<sub>1-6</sub>alkylcarbonyl; C<sub>1-6</sub>alkyloxyC<sub>1-6</sub>alkyl; C<sub>1-6</sub>alkylsulfonyl; cyanoC<sub>1-6</sub>alkyl; hydroxyC<sub>1-6</sub>alkyl; hydroxyC<sub>1-6</sub>alkyloxy; hydroxyC<sub>1-6</sub>alkylamino; aminoC<sub>1-6</sub>alkyloxy; di(C<sub>1-6</sub>alkyl)aminocarbonyl; di(hydroxyC<sub>1-6</sub>alkyl)amino; (aryl)(C<sub>1-6</sub>alkyl)amino; di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyloxy; di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkylamino; di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkylaminoC<sub>1-6</sub>alkyl; arylsulfonyl; arylsulfonylamino; aryloxy; aryloxyC<sub>1-6</sub>alkyl; arylC<sub>2-6</sub>alkenediyl; di(C<sub>1-6</sub>alkyl)amino; di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl; di(C<sub>1-6</sub>alkyl)amino(C<sub>1-6</sub>alkyl)amino; di(C<sub>1-6</sub>alkyl)amino(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl; di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl(C<sub>1-6</sub>alkyl)amino; di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl; aminosulfonylamino(C<sub>1-6</sub>alkyl)amino; aminosulfonylamino(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl; di(C<sub>1-6</sub>alkyl)aminosulfonylamino(C<sub>1-6</sub>alkyl)amino; di(C<sub>1-6</sub>alkyl)aminosulfonylamino(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl; cyano; (hydroxyC<sub>1-6</sub>alkyl)(C<sub>1-6</sub>alkyl)amino; (hydroxyC<sub>1-6</sub>alkyl)(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl; hydroxyC<sub>1-6</sub>alkylaminoC<sub>1-6</sub>alkyl; di(hydroxyC<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl; phenyl; phenyl substituted with one, two or three substituents independently selected from halo, amino, nitro, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, hydroxyC<sub>1-4</sub>alkyl, trifluoromethyl, trifluoromethyloxy, hydroxyC<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyl, aminoC<sub>1-4</sub>alkyloxy, di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyloxy, di(C<sub>1-4</sub>alkyl)amino, di(C<sub>1-4</sub>alkyl)aminocarbonyl, di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl,


Docket No.: PRD-2014USPCT

U.S.S.N. 10/507,084

di(C<sub>1-4</sub>alkyl)amino(C<sub>1-4</sub>alkyl)amino, di(C<sub>1-4</sub>alkyl)amino(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl(C<sub>1-4</sub>alkyl)amino,  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,  
aminosulfonylamino(C<sub>1-4</sub>alkyl)amino,  
aminosulfonylamino(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,  
di(C<sub>1-4</sub>alkyl)aminosulfonylamino(C<sub>1-4</sub>alkyl)amino,  
di(C<sub>1-4</sub>alkyl)aminosulfonylamino(C<sub>1-4</sub>alkyl)aminoC<sub>1-6</sub>alkyl, cyano,  
(hydroxyC<sub>1-4</sub>alkyl)(C<sub>1-4</sub>alkyl)amino, (hydroxyC<sub>1-4</sub>alkyl)(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,  
hydroxyC<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl, di(hydroxyC<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,  
hydroxyC<sub>1-4</sub>alkylamino, di(hydroxyC<sub>1-4</sub>alkyl)amino, or  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkylamino;  
aryl in the above is phenyl, or phenyl substituted with one or more substituents each  
independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, trifluoromethyl, cyano or  
hydroxycarbonyl.

29. (previously presented) A compound as claimed in claim 28 wherein

R<sup>3</sup> and R<sup>4</sup> are each independently selected from hydrogen, hydroxy, hydroxyC<sub>1-6</sub>alkyl,  
aminoC<sub>1-6</sub>alkyl or aminoaryl;

— is a radical selected from (a-1), (a-20), (a-21), (a-28), or (a-29);

R<sup>5</sup> is selected from hydrogen; phenyl; or phenyl substituted with one, two or three  
substituents independently selected from halo, amino, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy,  
hydroxyC<sub>1-4</sub>alkyl, trifluoromethyl, trifluoromethyloxy, hydroxyC<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>  
alkyloxyC<sub>1-4</sub>alkyloxy,  
aminoC<sub>1-4</sub>alkyloxy,  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyloxy, di(C<sub>1-4</sub>alkyl)amino, di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, di(C<sub>1-4</sub>  
alkyl)aminoC<sub>1-4</sub>alkyl(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkylamino, di(hydroxyC<sub>1-4</sub>  
alkyl)amino, or  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkylamino.


R<sup>6</sup> is selected from hydrogen; halo; hydroxy; amino; nitro; trihaloC<sub>1-6</sub>alkyl; trihaloC<sub>1-6</sub>  
alkyloxy; C<sub>1-6</sub>alkyl; C<sub>1-6</sub>alkyloxy;  
C<sub>1-6</sub>alkyloxyC<sub>1-6</sub>alkyloxy; C<sub>1-6</sub>alkylcarbonyl; C<sub>1-6</sub>alkylsulfonyl; cyanoC<sub>1-6</sub>alkyl;  
hydroxyC<sub>1-6</sub>alkyl; hydroxyC<sub>1-6</sub>alkyloxy; hydroxyC<sub>1-6</sub>alkylamino;

Docket No.: PRD-2014USPCT  
U.S.S.N. 10/507,084

aminoC<sub>1-6</sub>alkyloxy; di(C<sub>1-6</sub>alkyl)aminocarbonyl; di(hydroxyC<sub>1-6</sub>alkyl)amino;  
arylC<sub>1-6</sub>alkyl)amino; di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyloxy;  
di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkylamino; arylsulfonyl; arylsulfonylamino; aryloxy;  
arylC<sub>2-6</sub>alkenediyl; di(C<sub>1-6</sub>alkyl)amino;  
di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl;  
di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl; cyano; thiophenyl; thiophenyl  
substituted with di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl,  
di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl, or  
di(hydroxyC<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl;  
(hydroxyC<sub>1-6</sub>alkyl)(C<sub>1-6</sub>alkyl)amino; (hydroxyC<sub>1-6</sub>alkyl)(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl; or  
phenyl optionally substituted with one, two or three substituents independently selected  
from halo, amino, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, hydroxyC<sub>1-4</sub>alkyl, trifluoromethyl,  
trifluoromethyloxy, hydroxyC<sub>1-4</sub>alkyloxy, C<sub>1-4</sub>alkyloxyC<sub>1-4</sub>alkyloxy, aminoC<sub>1-4</sub>alkyloxy,  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyloxy, di(C<sub>1-4</sub>alkyl)amino, di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, di(C<sub>1-4</sub>  
alkyl)aminoC<sub>1-4</sub>alkyl(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,  
(hydroxyC<sub>1-4</sub>alkyl)(C<sub>1-4</sub>alkyl)amino, (hydroxyC<sub>1-4</sub>alkyl)(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl,  
hydroxyC<sub>1-4</sub>alkylamino, di(hydroxyC<sub>1-4</sub>alkyl)amino, or  
di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkylamino.

30. (previously presented) A compound as claimed in claim 28 wherein t is 0;

R<sup>1</sup> is -C(O)NR<sup>3</sup>R<sup>4</sup>, -C(O)-C<sub>1-6</sub>alkanediylSR<sup>7</sup>, -NR<sup>6</sup>C(O)N(OH)R<sup>7</sup>,  
-NR<sup>6</sup>C(O)C<sub>1-6</sub>alkanediylSR<sup>7</sup> or -NR<sup>6</sup>C(O)C=N(OH)R<sup>7</sup> wherein R<sup>3</sup> and R<sup>4</sup> are each  
independently selected from hydrogen, hydroxy, hydroxyC<sub>1-6</sub>alkyl or aminoC<sub>1-6</sub>alkyl; R<sup>2</sup> is  
hydrogen, hydroxy, amino,  
hydroxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, arylC<sub>1-6</sub>alkyl, aminocarbonyl,  
aminoC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylaminoC<sub>1-6</sub>alkyl or di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl;  
-L- is a bivalent radical selected from -NHC(O)- or -NHSO<sub>2</sub>-;

— is a radical selected from (a-1), (a-20),  
(a-21), (a-28), or (a-48);


each s is independently 0, 1, 2, 3 or 4;

R<sup>5</sup> is hydrogen, phenyl or phenyl substituted with one or two substituents independently  
selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy or trifluoromethyl;

and R<sup>6</sup> is hydrogen, phenyl; or phenyl substituted with one or two substituents  
independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy or trifluoromethyl.

Docket No.: PRD-2014USPCT  
U.S.S.N. 10/507,084


31. (previously presented) A compound as claimed in claim 28 wherein t is 0 or 1; each Q


is ; each X is nitrogen; R<sup>1</sup> is -C(O)NH(OH); R<sup>2</sup> is hydrogen, hydroxy, C<sub>1</sub>-6alkyl,

or arylC<sub>1</sub>-6alkyl; -L- is a bivalent radical selected from -NHC(O)- or -NHSO<sub>2</sub>-;  is a radical selected from (a-1) or (a-20); each s is independently 0 or 1; and each R<sup>5</sup> is





independently selected from hydrogen or phenyl.

32. (previously presented) A compound as claimed in claim 28 wherein t is 1; each Q is


; each X is nitrogen; each Y is nitrogen; each Z is -O-; R<sup>1</sup> is -C(O)NH(OH); R<sup>2</sup> is

hydrogen; -L- is a bivalent radical selected from -NHC(O)- or -NHSO<sub>2</sub>-;  is a radical selected from (a-1) or (a-20); each s is independently 0 or 1; and each R<sup>5</sup> is independently selected from hydrogen or phenyl.

33. (currently amended) A compound according to claim 28 selected from the following compounds ~~No 4, No 10, No 8, No 6, No 1, No 12 and No 14~~ :

|   |   |
|---|---|
|  <p style="text-align: center;"><b>Co. No. 4</b></p> |  <p style="text-align: center;"><b>Co. No. 10</b></p> |
|  <p style="text-align: center;"><b>Co. No. 8</b></p> |  <p style="text-align: center;"><b>Co. No. 6</b></p>  |

Docket No.: PRD-2014USPCT  
U.S.S.N. 10/507,084



34. (previously presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 28.
35. (currently amended) A pharmaceutical composition combination of anti-cancer agents and a compound of claim 28.
36. (previously presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 33.
37. (currently amended) A pharmaceutical composition combination of anti-cancer agents and a compound of claim 33.